KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Invested Capital (2016 - 2025)

CRISPR Therapeutics AG's Invested Capital history spans 11 years, with the latest figure at $1.9 billion for Q4 2025.

  • For Q4 2025, Invested Capital fell 0.53% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, down 0.53%, while the annual FY2025 figure was $1.9 billion, 0.53% down from the prior year.
  • Invested Capital for Q4 2025 was $1.9 billion at CRISPR Therapeutics AG, roughly flat from $1.9 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $2.6 billion in Q2 2021 and bottomed at $1.7 billion in Q2 2025.
  • The 5-year median for Invested Capital is $1.9 billion (2024), against an average of $2.0 billion.
  • The largest annual shift saw Invested Capital skyrocketed 185.92% in 2021 before it dropped 22.24% in 2022.
  • A 5-year view of Invested Capital shows it stood at $2.4 billion in 2021, then fell by 21.84% to $1.9 billion in 2022, then rose by 0.39% to $1.9 billion in 2023, then rose by 2.62% to $1.9 billion in 2024, then dropped by 0.53% to $1.9 billion in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Invested Capital are $1.9 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.7 billion (Q2 2025).